The FAS consisted of 627 patients (olmesartan medoxomil 40 mg/day, n = 302 ... of events probably or definitely related to study drug was low (6.4%). Serious adverse events (n = 10) occurred ...
During the randomised phase of the study, both treatments were associated with further improvements in sitting SBP/DBP: a reduction of 5.3/5.1mm Hg with olmesartan medoxomil 40 mg/day, and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback